A polyp found and removed before it becomes malignant is a life preserved.
Em um país onde o câncer colorretal avança silenciosamente e mata com crescente frequência, o Brasil decidiu agir antes que os sintomas falem. O Ministério da Saúde incorporou ao SUS o teste imunoquímico fecal como ferramenta padrão de rastreamento, oferecendo a mais de 40 milhões de adultos assintomáticos entre 50 e 75 anos uma chance de encontrar a doença quando ela ainda pode ser vencida. É o reconhecimento de que a medicina mais poderosa nem sempre é a mais complexa — às vezes, é a que chega à porta de casa a tempo.
- O câncer colorretal projeta 53.800 novos casos por ano no Brasil, com mortes que podem triplicar até 2030 se nada mudar.
- A maioria dos pacientes brasileiros só descobre a doença em estágio avançado, quando as opções de tratamento já são mais limitadas e a sobrevida, menor.
- O teste FIT detecta rastros invisíveis de sangue nas fezes com 85 a 92% de sensibilidade, identificando pólipos e lesões pré-cancerosas antes que evoluam.
- A coleta é feita em casa, sem dieta especial, sem preparo intestinal e sem procedimento invasivo — barreiras eliminadas para aumentar a adesão em massa.
- Resultados positivos acionam a colonoscopia, onde médicos podem visualizar e remover pólipos diretamente, interrompendo o ciclo antes do câncer se instalar.
O Ministério da Saúde anunciou na quinta-feira a incorporação do teste imunoquímico fecal — o FIT — como padrão de rastreamento do câncer colorretal no SUS. O público-alvo são homens e mulheres assintomáticos entre 50 e 75 anos, uma faixa que pode reunir mais de 40 milhões de brasileiros.
O câncer colorretal é o segundo mais comum no país, excluídos os de pele, com projeção de 53.800 novos casos anuais até 2028. O cenário futuro é sombrio: sem intervenção organizada, as mortes pela doença devem quase triplicar até 2030. O problema central não é a existência do câncer, mas o momento em que ele é descoberto — na maioria dos casos, tarde demais.
O FIT funciona detectando traços microscópicos de sangue nas fezes por meio de anticorpos específicos que identificam sangue humano com precisão, reduzindo resultados falsos. A sensibilidade do exame varia entre 85% e 92%. Sua grande vantagem está na simplicidade: o paciente coleta a amostra em casa, sem preparo especial, e envia ao laboratório pelo correio. Não há necessidade de jejum, dieta restritiva ou sedação.
Quando o resultado é positivo, o próximo passo é a colonoscopia — exame que permite visualizar diretamente o intestino e remover pólipos antes que se tornem malignos. Essa combinação entre acessibilidade e eficácia é o coração da estratégia: quanto menos oneroso o rastreamento, maior a adesão — e maior a chance de encontrar a doença cedo, quando o tratamento ainda funciona melhor.
A decisão do Ministério representa uma aposta na simplicidade como motor de alcance. O sucesso da medida dependerá da implementação efetiva pelo sistema e de quantos dos 40 milhões de brasileiros elegíveis chegarão, de fato, a realizar o exame.
Brazil's health system is adopting a new weapon against one of the country's deadliest cancers. On Thursday, the Health Ministry announced that the immunochemical fecal test—known by its English acronym FIT—will become the standard screening tool for colorectal cancer across the public health system. The test targets asymptomatic men and women between 50 and 75 years old, a population that could number more than 40 million people.
Colorectal cancer ranks as Brazil's second most common malignancy when skin cancers are excluded. The National Cancer Institute projects 53,800 new cases annually through 2028. The numbers are darkening: deaths from this disease are expected to nearly triple by 2030. The tragedy is not that the cancer exists, but that most Brazilians discover it only after it has already advanced beyond the point where treatment is most effective. Organized screening exists precisely to prevent that discovery from coming too late.
The FIT works by detecting microscopic traces of blood in stool—blood so faint the human eye cannot see it. These hidden traces can signal the presence of polyps, pre-cancerous lesions, or cancer itself developing in the colon or rectum. What distinguishes this test from older blood-in-stool exams is its use of specific antibodies that identify human blood with precision, reducing false results and improving reliability. Studies show the test catches between 85 and 92 percent of significant abnormalities.
The practical elegance of FIT lies in its simplicity. A patient receives a collection kit to use at home—no special diet required, no bowel preparation needed, no invasive procedure. A single sample suffices. The kit is mailed to a laboratory for analysis. If blood is detected, the patient moves to the next step: colonoscopy, the gold standard for examining the colon and rectum. During colonoscopy, doctors can visualize the entire organ directly and remove polyps on the spot, preventing some lesions from ever becoming cancer.
This combination of ease and effectiveness matters enormously for a public health system serving millions. The less burdensome a screening test, the more people will actually take it. The FIT requires no restrictive preparation, no fasting, no sedation. It is less invasive than colonoscopy alone would be as a first-line screen. These qualities translate into higher participation rates—the difference between a program that reaches the people it aims to protect and one that sits on the shelf.
The timing of this adoption reflects a growing urgency. Colorectal cancer in Brazil is not static; it is accelerating. Without intervention, the trajectory points toward substantially more deaths in the coming years. Early detection through screening offers one of the few proven ways to interrupt that arc. A polyp found and removed before it becomes malignant is a life preserved. A cancer caught at stage one rather than stage four is a fundamentally different clinical problem.
The Health Ministry's decision to make FIT the reference standard across SUS represents a significant shift in how the country approaches this particular disease. It is a bet that accessibility and simplicity will drive participation, and that participation will catch disease earlier, when treatment works better and survival rates are higher. Whether that bet pays off will depend on how thoroughly the system implements the protocol and how many of those 40 million eligible Brazilians actually receive the test.
Citas Notables
The test presents sensitivity between 85% and 92% for identifying possible alterations— Health Ministry
La Conversación del Hearth Otra perspectiva de la historia
Why does this test matter more than what Brazil was doing before?
Because most people with colorectal cancer don't know they have it until it's already spread. This test finds it when it's still just a polyp, before it becomes cancer at all.
But colonoscopy already exists. Why not just screen everyone with that?
Colonoscopy is the gold standard, but it's invasive. It requires sedation, bowel prep, a procedure room. Most people avoid it if they can. FIT is a stool sample you do at home. The barrier to entry is almost nothing.
So FIT is a filter—it catches the people who need colonoscopy?
Exactly. You screen 100 people with FIT. Maybe five test positive. Those five get colonoscopy. The other 95 avoid an unnecessary procedure and still get screened.
What happens if FIT misses something?
It catches 85 to 92 percent of significant lesions. That's not perfect, but it's far better than catching nothing. And the people it misses are usually those with smaller, slower-growing polyps.
Why is Brazil announcing this now?
Deaths from colorectal cancer are projected to nearly triple by 2030. The country is watching the problem accelerate. This is an attempt to get ahead of it before the crisis deepens.
Will 40 million people actually get tested?
That's the real question. Having a good test and actually reaching people are two different things. The system has to distribute kits, process results, follow up on positives. The test is only as good as the infrastructure behind it.